Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker

2016 ◽  
Vol 23 (7) ◽  
pp. 937-945 ◽  
Author(s):  
Teresa Órpez-Zafra ◽  
Jose Pavía ◽  
Isaac Hurtado-Guerrero ◽  
Maria J Pinto-Medel ◽  
Jose Luis Rodriguez Bada ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
First Year ◽  
Diagnostic Biomarker ◽  
Lower Serum ◽  
Cross Sectional ◽  
Treatment Naïve ◽  
Β Receptor ◽  
Multiple Sclerosis Patients

Background: The soluble isoform of the interferon-β (IFN-β) receptor (sIFNAR2) could modulate the activity of both endogenous and systemically administered IFN-β. Previously, we described lower serum sIFNAR2 levels in untreated multiple sclerosis (MS) than in healthy controls (HCs). Objective: To assess sIFNAR2 levels in a new cohort of MS patients and HCs, as well as in patients with clinically isolated syndrome (CIS) and with other inflammatory neurological disorders (OIND) and to assess its ability as a diagnostic biomarker. Methods: The cross-sectional study included 148 MS (84 treatment naive and 64 treated), 87 CIS, 42 OIND, and 96 HCs. Longitudinal study included 94 MS pretreatment and after 1 year of therapy with IFN-β, glatiramer acetate (GA), or natalizumab. sIFNAR2 serum levels were measured by a quantitative ELISA developed and validated in our laboratory. Results: Naive MS and CIS patients showed significantly lower sIFNAR2 levels than HCs and OIND patients. The sensitivity and specificity to discriminate between MS and OIND, for a sIFNAR2 cutoff value of 122.02 ng/mL, were 70.1%, and 79.4%, respectively. sIFNAR2 increased significantly in IFN-β-treated patients during the first year of therapy in contrast to GA- and natalizumab-treated patients who showed non-significant changes. Conclusion: The results suggest that sIFNAR2 could be a potential diagnostic biomarker for MS.

Quality of life in multiple sclerosis patients in Spain

2002 ◽  
Vol 8 (6) ◽  
pp. 527-531 ◽  
Author(s):  
C-H Chang ◽  
D Cella ◽  
O Fernández ◽  
G Luque ◽  
P de Castro ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Well Being ◽  
Cross Sectional Study ◽  
Self Report ◽  
Regression Analyses ◽  
Cross Sectional ◽  
Scale Scores ◽  
Multiple Sclerosis Patients

Objective: The cross-sectional study evaluated the psychometric properties of the Functional Assessment of Multiple Sclerosis (FAMS) Spanish version and its use in measuring quality of life (QOL) of multiple sclerosis (MS) patients in Spain. Methods: The FAMS is a factorially derived self-report scale designed to assess six primary aspects of QOL of patients with MS: Mobility, Symptoms, Emotional Well-Being, General Contentment, Thinking and Fatigue, and Family/Social Well-Being. Its Spanish translated version was used to assess QOL of 625 MS patients recruited in an outpatient clinic setting from 58 hospitals in Spain. Internal consistency of the Spanish FAMS was evaluated. Multiple regression analyses were performed to identify significant predictors from demographic, clinical and treatment characteristics, and Kurtzke Expanded Disability Status Scale (EDSS) scores in predicting FAMS scale scores. Results: Most of the patients are females (66%), and 74% were of the relapsing-remitting (RR) clinical subtype. Cronbach’s alpha coefficients were high (range=0.78-0.96), indicating subscale homogeneity comparable to that of the original English version. Linear multivariate regression analyses revealed that the EDSS is a dominant variable in predicting all the FAMS subscales, especially mobility (R2=0.51) and the total scores. Conclusions: The Spanish FAMS is a psychometrically valid instrument that allows clinicians and clinical researchers the ability to measure the QOL concerns of MS patients in Spain.

Internet-based cognitive testing in multiple sclerosis

2007 ◽  
Vol 13 (8) ◽  
pp. 1011-1019 ◽  
Author(s):  
M. Younes ◽  
J. Hill ◽  
J. Quinless ◽  
M. Kilduff ◽  
B. Peng ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Function ◽  
Verbal Memory ◽  
Stability Index ◽  
Cross Sectional Study ◽  
Cognitive Testing ◽  
The Internet ◽  
Cross Sectional ◽  
Multiple Sclerosis Patients

Cognitive impairment in multiple sclerosis is difficult to study because of the heterogeneity and variability of this disease. The gold standard for measurement of cognitive function in multiple sclerosis is a full battery of neurocognitive tests, which is time consuming and expensive. Some cognitive tests like the PASAT, a measure of working verbal memory and processing speed, have been proposed for screening and follow-up of cognitive function in clinical trials. We studied whether we could measure cognitive function in multiple sclerosis over the Internet. For this we used the Cognitive Stability Index (CSI)™, developed for persons with known or suspected primary central nervous system illness. The CSI was compared with formal neurocognitive testing (NPsych) and the PASAT in a cross-sectional study of 40 consecutive multiple sclerosis patients with subjective cognitive complaints. NPsych revealed that only 18 of the 40 patients (46%) were cognitively impaired. Although both the CSI and the PASAT were equalivalent in their specificity (86%), the CSI was significantly more sensitive than the PASAT (83% versus 28%). We conclude that the CSI, because of its availability over the Internet, has great potential as a tool for screening and follow up of cognitive function in multiple sclerosis. Multiple Sclerosis 2007; 13: 1011—1019. http://msj.sagepub.com

scholarly journals Is the Concept of Quality of Life Relevant for Multiple Sclerosis Patients with Cognitive Impairment? Preliminary Results of a Cross-Sectional Study

PLoS ONE ◽  
2012 ◽  
Vol 7 (1) ◽  
pp. e30627 ◽  
Author(s):  
Karine Baumstarck ◽  
Jean Pelletier ◽  
Valérie Aghababian ◽  
Françoise Reuter ◽  
Irina Klemina ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Preliminary Results ◽  
Multiple Sclerosis Patients

Associations between functional capacity, isokinetic leg strength, sleep quality and cognitive function in multiple sclerosis patients: a cross-sectional study

2019 ◽  
Vol 131 (7) ◽  
pp. 453-460 ◽  
Author(s):  
Panayiotis Aristotelous ◽  
Manos Stefanakis ◽  
Marios Pantzaris ◽  
Constantinos Pattichis ◽  
Georgios M Hadjigeorgiou ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Function ◽  
Sleep Quality ◽  
Functional Capacity ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Leg Strength ◽  
Multiple Sclerosis Patients

scholarly journals High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis

2018 ◽  
Vol 4 (3) ◽  
pp. 205521731878869 ◽  
Author(s):  
Alexander Lau ◽  
Wei Qiu ◽  
Allan Kermode ◽  
Cheryl Au ◽  
Angel Ng ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cross Sectional Study ◽  
Chinese Patients ◽  
Virus Antibody ◽  
Cross Sectional ◽  
John Cunningham Virus ◽  
High Prevalence ◽  
Scale Scores ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients

We performed a cross-sectional study in 123 Chinese multiple sclerosis patients residing in Hong Kong to evaluate their anti-John Cunningham virus status using STRATIFY JCV DxSelect assays. Anti-John Cunningham virus antibody was present in 98/123 (80%) subjects, among which 75/98 (77%) had an anti-John Cunningham virus index ≥1.5. Anti-John Cunningham virus antibody seropositivity was not correlated with age, disease duration, Expanded Disability Status Scale scores, types of multiple sclerosis (relapsing vs progressive), or disease-modifying treatments used. We found a very high seroprevalence and index of anti-John Cunningham virus antibodies in Chinese multiple sclerosis patients, which may impact the risk assessment and recommendation of disease-modifying treatments in this population.

Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis

2008 ◽  
Vol 14 (9) ◽  
pp. 1220-1224 ◽  
Author(s):  
J Smolders ◽  
P Menheere ◽  
A Kessels ◽  
J Damoiseaux ◽  
R Hupperts
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Relapse Rate ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
Vitamin D Supplementation ◽  
Biologically Active ◽  
Serum Samples ◽  
Cross Sectional ◽  
Edss Score

Background Multiple Sclerosis is associated with low serum levels of 25-hydroxyvitamin D (25(OH)D). We investigated the association between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite, and clinical MS severity as expressed by EDSS-score and relapse rate. Study-design Cross-sectional study. Patients and Methods Serum samples from 267 MS patients were collected for 25(OH)D and 1,25(OH)2D measurement. Clinical MS parameters at the date of serum sampling were determined. Results: Both metabolite levels were significantly lower in the progressive forms compared to the relapsing remitting (RR)MS phenotype. In RRMS patients (disease course ≤ 5 years), high 25(OH)D levels were associated with a high chance of remaining relapse-free. Low 25(OH)D levels were associated with high EDSS-scores. 1,25(OH)2D was not directly associated with relapse rate or EDSS-score, and was dependent of age and 25(OH)D level. Conclusion Serum levels of 25(OH)D were associated with both relapse rate and disability in MS patients. These results are suggestive for a disease modulating effect of the serum concentrations of 25(OH)D on MS. The low circulating 1,25(OH)2D levels in progressive MS are due to older age and lower 25(OH)D levels. The potential consequences for vitamin D supplementation in MS will be discussed.

scholarly journals Clinical features in adult multiple sclerosis patients

2020 ◽  
Vol 54 (2) ◽  
pp. 104-112
Author(s):  
Matej Koprivnik ◽  
Tanja Hojs Fabjan
Keyword(s):  
Multiple Sclerosis ◽  
Negative Correlation ◽  
Berg Balance Scale ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Positive Correlation ◽  
Disability Status ◽  
Serial Addition ◽  
Multiple Sclerosis Patients ◽  
Eq Vas

Introduction: The purpose of the study was to identify possible correlations between the quality of life, neurological disability, and functional ability in patients with multiple sclerosis.Methods: 258 patients with multiple sclerosis were included in the cross-sectional study. They were assessed with the Expanded Disability Status Scale (EDSS), the Berg Balance Scale (BBS), the Timed 25-Foot Walk Test (T25-FW), the 9-Hole Peg Test (9HPT), the Paced Auditory Serial Addition Test (PASAT-3) and the EQ visual analogue scale (EQ-VAS). Inferential statistics were used.Results: A positive correlation between the EQ-VAS and the BBS (r = 0.43, p < 0.01 ) and the PASAT-3 (r =¸0.19, p < 0.01), and a negative correlation between the EQ-VAS and the T25FW (r = –0.42, p < 0.01) and the 9-HPT (r = –0.40, p < 0.01) were shown. A negative correlation was also observed between the EDSS and the BBS (r = –0.77, p < 0.05) as well as the EDSS and the PASAT-3 (r = –0.25, p < 0.01), and a positive correlation between the EDSS and the 9 HPT (r = 0.67, p < 0.01) and the T25-FW (r = 0.80, p < 0.01).Discussion and conclusion: Associations between the variables indicate the need for complex, personalized and rational monitoring of patients with multiple sclerosis.

Sign in / Sign up

Export Citation Format

Share Document